公开(公告)号：WO2006113289A3

公开(公告)日：2006-10-26

申请号：PCT/US2006/013727

申请日：2006-04-11

Applicant: VERMILLION, INC. ,  DAVIES, Huw, Alun ,  BLENNOW, Kaj ,  MCGUIRE, James, Norton ,  PODUST, Vladimir, N. ,  SIMONSEN, Anja, Hviid

Inventor： DAVIES, Huw, Alun ,  BLENNOW, Kaj ,  MCGUIRE, James, Norton ,  PODUST, Vladimir, N. ,  SIMONSEN, Anja, Hviid

IPC: C07H21/02 ,  C07H21/04 ,  G01N33/53 ,  G01N33/567

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The biomarkers can be detected by SELDI mass spectrometry.

公开(公告)号：WO2009100953A3

公开(公告)日：2009-08-20

申请号：PCT/EP2009/001210

申请日：2009-02-13

Applicant: MEDINNOVA AS ,  FLADBY, Tormod ,  JOHNSEN, Lisbeth ,  BLENNOW, Kaj

Inventor： FLADBY, Tormod ,  JOHNSEN, Lisbeth ,  BLENNOW, Kaj

IPC: G01N33/569 ,  G01N33/68

Abstract: A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and/or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein.

公开(公告)号：WO2005047484A3

公开(公告)日：2007-06-07

申请号：PCT/US2004037994

申请日：2004-11-06

Applicant: CIPHERGEN BIOSYSTEMS INC ,  DAVIES HUW ALUN ,  MCGUIRE JAMES ,  SIMONSEN ANJA HVIID ,  BLENNOW KAJ ,  PODUST VLADIMIR

Inventor： DAVIES HUW ALUN ,  MCGUIRE JAMES ,  SIMONSEN ANJA HVIID ,  BLENNOW KAJ ,  PODUST VLADIMIR

IPC: G01N33/50 ,  C12N20060101 ,  G01N33/48 ,  G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6896 ,  G01N33/6842 ,  G01N33/6848 ,  G01N33/6851 ,  G01N2800/2821

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).

Abstract translation: 本发明提供了可用于评估患者中的阿尔茨海默病状态的基于蛋白质的生物标志物和生物标志物组合。 特别地，本发明的生物标志物可用于将受试者样品分类为阿尔茨海默氏症或非阿尔茨海默氏痴呆或正常。 生物标志物可以通过SELDI质谱检测。 此外，本发明提供适当的治疗干预措施和测量治疗反应的方法。 本发明的某些生物标志物也可适用于诸如正电子发射断层扫描（PET）的非侵入性成像技术中的放射性标记的配体。

公开(公告)号：WO2006138325A3

公开(公告)日：2007-05-31

申请号：PCT/US2006023044

申请日：2006-06-13

Applicant: CIPHERGEN BIOSYSTEMS INC ,  DAVIES HUW ALUN ,  BLENNOW KAJ ,  MCGUIRE JAMES ,  PODUST VLADIMIR ,  SIMONSEN ANJA HVIID

Inventor： DAVIES HUW ALUN ,  BLENNOW KAJ ,  MCGUIRE JAMES ,  PODUST VLADIMIR ,  SIMONSEN ANJA HVIID

IPC: G01N33/00 ,  G01N33/563 ,  G06F11/30 ,  G06F12/00

CPC classification number: G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

Abstract: The present invention provides a neurosecretory protein VGF peptide useful in qualifying Alzheimer's disease status in a patient. In particular, this peptide and modified forms thereof may be used to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The peptide biomarker can be detected by SELDI mass spectrometry.

Abstract translation: 本发明提供了可用于评估患者中阿尔茨海默病状态的神经分泌蛋白VGF肽。 特别地，该肽及其修饰形式可用于将受试者样品分类为阿尔茨海默病或非阿尔茨海默氏病。 肽生物标志物可以通过SELDI质谱法检测。

公开(公告)号：WO2006113289A2

公开(公告)日：2006-10-26

申请号：PCT/US2006013727

申请日：2006-04-11

Applicant: CIPHERGEN BIOSYSTEMS INC ,  DAVIES HUW ALUN ,  BLENNOW KAJ ,  MCGUIRE JAMES NORTON ,  PODUST VLADIMIR N ,  SIMONSEN ANJA HVIID

Inventor： DAVIES HUW ALUN ,  BLENNOW KAJ ,  MCGUIRE JAMES NORTON ,  PODUST VLADIMIR N ,  SIMONSEN ANJA HVIID

IPC: G01N33/53 ,  G01N33/48 ,  G01N33/50 ,  G06F19/00

CPC classification number: G01N33/6896 ,  G01N2333/475 ,  G01N2800/2821

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The biomarkers can be detected by SELDI mass spectrometry.

Abstract translation: 本发明提供了可用于评估患者中的阿尔茨海默病状态的基于蛋白质的生物标志物和生物标志物组合。 特别地，本发明的生物标志物可用于将受试者样品分类为阿尔茨海默病或非阿尔茨海默氏病。 生物标志物可以通过SELDI质谱检测。

公开(公告)号：WO2012142301A3

公开(公告)日：2013-01-10

申请号：PCT/US2012033343

申请日：2012-04-12

Applicant: QUANTERIX CORP ,  WILSON DAVID ,  ZETTERBERG JOHN HENRIK ,  BLENNOW KAJ ,  RANDALL JEFFREY D

Inventor： WILSON DAVID ,  ZETTERBERG JOHN HENRIK ,  BLENNOW KAJ ,  RANDALL JEFFREY D

IPC: G01N33/68 ,  G01N33/52 ,  G01N33/53

CPC classification number: G01N33/6896 ,  G01N33/54306 ,  G01N2333/47 ,  G01N2333/4709 ,  G01N2800/28 ,  G01N2800/52

Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract translation: 在一些实施方案中，本发明通常涉及确定患者从脑损伤恢复的治疗方案和/或预后的方法。 在一些实施方案中，脑损伤是由缺氧事件引起的。 在一些实施方案中，提供了用于确定含有或怀疑含有tau蛋白的患者样品中tau蛋白浓度的量度的方法。

公开(公告)号：WO2009100953A2

公开(公告)日：2009-08-20

申请号：PCT/EP2009001210

申请日：2009-02-13

Applicant: MEDINNOVA AS ,  JOHNSEN LISBETH ,  BLENNOW KAJ

Inventor： JOHNSEN LISBETH ,  BLENNOW KAJ

IPC: G01N33/569 ,  G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/56972 ,  G01N33/6848 ,  G01N2333/70596 ,  G01N2800/2821

Abstract: A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and/or fragments thereof in the macrophages is indicative of the presence of the condition in the patient.

Abstract translation: 一种检测患者脑中存在或监测特征在于存在标志蛋白片段的病症的严重程度的方法。 该方法包括：（i）提供包含从患者获得的巨噬细胞的样品; 和（ii）检测巨噬细胞中标记蛋白或其片段的存在。 在巨噬细胞中存在异常水平的标记蛋白和/或其片段表明患者中存在病症。

公开(公告)号：WO2006138325A2

公开(公告)日：2006-12-28

申请号：PCT/US2006/023044

申请日：2006-06-13

Applicant: CIPHERGEN BIOSYSTEMS, INC. ,  DAVIES, Huw Alun ,  BLENNOW, Kaj ,  MCGUIRE, James ,  PODUST, Vladimir ,  SIMONSEN, Anja Hviid

Inventor： DAVIES, Huw Alun ,  BLENNOW, Kaj ,  MCGUIRE, James ,  PODUST, Vladimir ,  SIMONSEN, Anja Hviid

IPC: G01N33/567 ,  A61K38/54

CPC classification number: G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

Abstract: The present invention provides a neurosecretory protein VGF peptide useful in qualifying Alzheimer's disease status in a patient. In particular, this peptide and modified forms thereof may be used to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The peptide biomarker can be detected by SELDI mass spectrometry.

Abstract translation: 本发明提供了可用于评估患者中阿尔茨海默病状态的神经分泌蛋白VGF肽。 特别地，该肽及其修饰形式可用于将受试者样品分类为阿尔茨海默病或非阿尔茨海默氏病。 肽生物标志物可以通过SELDI质谱法检测。

公开(公告)号：WO2005047484A2

公开(公告)日：2005-05-26

申请号：PCT/US2004/037994

申请日：2004-11-06

Applicant: CIPHERGEN BIOSYSTEMS, INC. ,  DAVIES, Huw, Alun ,  MCGUIRE, James ,  SIMONSEN, Anja, Hviid ,  BLENNOW, Kaj ,  PODUST, Vladimir

Inventor： DAVIES, Huw, Alun ,  MCGUIRE, James ,  SIMONSEN, Anja, Hviid ,  BLENNOW, Kaj ,  PODUST, Vladimir

IPC: C12N

CPC classification number: G01N33/6896 ,  G01N33/6842 ,  G01N33/6848 ,  G01N33/6851 ,  G01N2800/2821

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).

Abstract translation: 本发明提供了可用于评估患者中的阿尔茨海默病状态的基于蛋白质的生物标志物和生物标志物组合。 特别地，本发明的生物标志物可用于将受试者样品分类为阿尔茨海默病或非阿尔茨海默氏痴呆或正常。 生物标志物可以通过SELDI质谱检测。 此外，本发明提供适当的治疗干预措施和测量治疗反应的方法。 本发明的某些生物标志物也可适用于诸如正电子发射断层扫描（PET）的非侵入性成像技术中的放射性标记的配体。

公开(公告)号：WO2004104597A1

公开(公告)日：2004-12-02

申请号：PCT/EP2004/050684

申请日：2004-05-03

Applicant: INNOGENETICS N.V. ,  VANDERSTICHELE, Hugo ,  VANMECHELEN, Eugeen ,  BLENNOW, Kaj ,  DE MEYER, Geert ,  KOSTANJEVECKI, Vesna

Inventor： VANDERSTICHELE, Hugo ,  VANMECHELEN, Eugeen ,  BLENNOW, Kaj ,  DE MEYER, Geert ,  KOSTANJEVECKI, Vesna

IPC: G01N33/68

CPC classification number: C07K16/18 ,  G01N33/54306 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821

Abstract: Methods are provided for the prediction, diagnosis and differential diagnosis of Alzheimer's disease. More particularly, a method is provided to determine whether a subject that does not show any clinical signs of Alzheimer's disease has a likelihood to develop Alzheimer's disease. Further a method is provided for the diagnosis of subjects suffering from Alzheimer's disease and/or for the differential diagnosis of subjects suffering from Alzheimer's disease versus subjects suffering from other dementias such as dementia with Lewy bodies. The methods are based on the determination of the ratio of specific Aβ peptides.

Abstract translation: 为阿尔茨海默病的预测，诊断和鉴别诊断提供方法。 更具体地，提供了一种确定不显示任何阿尔茨海默病临床症状的受试者是否有发生阿尔茨海默氏病的可能性的方法。 此外，提供了一种用于诊断患有阿尔茨海默氏病的受试者和/或用于对患有阿尔茨海默病的受试者进行鉴别诊断的受试者与患有其他痴呆症的患者（例如路易体痴呆症）的方法。 该方法基于确定特异性Aβ肽的比例。